Body Surface Area-Based Dosing of Infliximab is Superior to Standard Weight-Based Dosing in Children With Very Early Onset Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Body Surface Area-Based Dosing of Infliximab is Superior to Standard Weight-Based Dosing in Children With Very Early Onset Inflammatory Bowel Disease

Published:2024 Issue:2 Volume:3 Page:215-220
ISSN:2772-5723
Container-title:Gastro Hep Advances
language:en
Short-container-title:Gastro Hep Advances

Author:

Stallard Lorraine^ORCID,Frost Karen,Frost Nathaniel,Scarallo Luca,Benchimol Eric I.,Walters Thomas D.,Church Peter C.,Griffiths Anne M.,Muise Aleixo M.^ORCID,Ricciuto Amanda^ORCID

Funder

CIHR

Publisher

Elsevier BV

Reference14 articles.

1. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review;Kuenzig;Gastroenterology,2022

2. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study;Dotan;Inflamm Bowel Dis,2014

3. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study;Bramuzzo;United European Gastroenterol J,2019

4. Infliximab in young paediatric IBD patients: it is all about the dosing;Jongsma;Eur J Pediatr,2020

5. Rational development and utilization of antibody-based therapeutic proteins in pediatrics;Xu;Pharmacol Ther,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TNF inhibitors as a treatment of pediatric IBD;Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology;2024-08-20

2. Updates In The Management Of Pediatric Inflammatory Bowel Disease;Canadian IBD Today;2024-06-05